CRIS · Curis Inc · Webcasts, Transcripts & Audio
$0.80
-0.03 (-3.29%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with FASB ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.78M
Shares
2.09M
Volume · Oct 2
100.35K
Avg daily vol (64 sessions)
187.31K
Curis Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Curis Inc (CRIS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲4.7%
$2.39M
−$15.94M
'22 Q2
22-08-04
▼7%
$2.83M
−$13.29M
'22 Q3
22-11-09
▼7.9%
$2.89M
−$11.33M
'22 Q4
23-03-13
▲11.7%
$2.30M
−$11.56M
'23 Q1
23-05-04
▼8.2%
$2.20M
−$11.96M
'23 Q2
23-08-03
▲0.3%
$2.83M
−$12.18M
'23 Q3
23-11-02
▼6.6%
$2.70M
−$11.71M
'23 Q4
24-02-08
▼9.2%
$2.09M
−$11.88M
'24 Q1
24-05-07
▲15.9%
$2.55M
−$11.80M
'24 Q2
24-08-01
▲3.5%
$2.93M
−$10.09M
'24 Q3
24-11-14
▲24.1%
$3.35M
−$9.62M
'24 Q4
25-03-31
▲14.1%
$2.38M
−$10.62M
'25 Q1
25-05-06
▲8%
$2.75M
−$8.59M
'25 Q2
25-08-05
▲8.4%
$3.18M
−$7.73M
'25 Q3
25-11-06
▼66%
$1.14M
$19.36M
'25 Q4
26-03-19
LATEST
▼100%
$
−$24.20M
'26 Q1
26-05-12
Earnings call
FY26 · Q1
2026-05-12
Curis Inc (CRIS) Q1 2026 Earnings Call Transcript
Positive tone
TakeAim CLL proof-of-concept study
TakeAim Lymphoma / PCNSL registrational study
Emavusertib differentiation in CLL
Revenue
$
▼ 100% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Curis Inc (CRIS) Q4 2025 Earnings Call Transcript
Confident tone
Emavusertib + ibrutinib in CLL proof-of-concept
TakeAim Lymphoma / PCNSL registrational study
Regulatory pathway (FDA/EMA)
Revenue
$1.14M*
▼ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Curis Inc (CRIS) Q3 2025 Earnings Call Transcript
Positive tone
CLL Program Expansion
AML Triplet Study (Aza-Ven + Emavusertib)
PCNSL (Primary CNS Lymphoma) TakeAim Lymphoma Study
Revenue
$3.18M
▲ 8.4% YoY Diluted EPS
$-9.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Curis Inc (CRIS) Q2 2025 Earnings Call Transcript
Confident tone
TakeAim Lymphoma / PCNSL study
Frontline AML triplet study
CLL proof-of-concept study
Revenue
$2.75M
▲ 8% YoY Diluted EPS
$-13.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Curis Inc (CRIS) Q1 2025 Earnings Call Transcript
Positive tone
Emavusertib in PCNSL (TakeAim Lymphoma study)
Emavusertib in AML
Regulatory pathway / FDA and EMA engagement
Revenue
$2.38M
▲ 14.1% YoY Diluted EPS
$-25.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Curis Inc (CRIS) Q4 2024 Earnings Call
Revenue
$3.35M*
▲ 24.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Curis Inc (CRIS) Q3 2024 Earnings Call Transcript
Positive tone
PCNSL study with ibrutinib combination
FDA regulatory engagement and accelerated approval
TakeAim Leukemia (AML) data
Revenue
$2.93M
▲ 3.5% YoY Diluted EPS
$-34.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Curis Inc (CRIS) Q2 2024 Earnings Call Transcript
Confident tone
TakeAim Leukemia study in AML
TakeAim Lymphoma / PCNSL study
IRAK4 mechanism and differentiation
Revenue
$2.55M
▲ 15.9% YoY Diluted EPS
$-40.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Curis Inc (CRIS) Q1 2024 Earnings Call Transcript
Confident tone
FLT3 mutation benchmark positioning
Emavusertib clinical progress in AML and lymphoma
Regulatory path and FDA discussions
Revenue
$2.09M
▼ 9.2% YoY Diluted EPS
$-41.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Curis Inc (CRIS) Q4 2023 Earnings Call Transcript
Confident tone
Emavusertib leukemia program (AML)
Solid tumor expansion (melanoma/IIT)
Primary CNS lymphoma (PCNSL) program
Revenue
$2.70M*
▼ 6.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Curis Inc (CRIS) Q3 2023 Earnings Call Transcript
Revenue
$2.83M
▲ 0.3% YoY Diluted EPS
$-42.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Curis Inc (CRIS) Q2 2023 Earnings Call Transcript
Revenue
$2.20M
▼ 8.2% YoY Diluted EPS
$-49.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Curis Inc (CRIS) Q1 2023 Earnings Call Transcript
Revenue
$2.30M
▲ 11.7% YoY Diluted EPS
$-47.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Curis Inc (CRIS) Q4 2022 Earnings Call Transcript
Revenue
$2.89M*
▼ 7.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Curis Inc (CRIS) Q3 2022 Earnings Call Transcript
Revenue
$2.83M
▼ 7% YoY Diluted EPS
$-56.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Curis Inc (CRIS) Q2 2022 Earnings Call Transcript
Revenue
$2.39M
▲ 4.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Curis Inc (CRIS) Q1 2022 Earnings Call Transcript
Revenue
$2.06M
▼ 6% YoY Diluted EPS
$-3.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Curis Inc (CRIS) Q4 2021 Earnings Call Transcript
Revenue
$3.13M*
▲ 3.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Curis Inc (CRIS) Q3 2021 Earnings Call Transcript
Revenue
$3.04M
▲ 10.8% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Curis Inc (CRIS) Q2 2021 Earnings Call Transcript
Revenue
$2.29M
▼ 3.1% YoY Diluted EPS
$-2.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Curis Inc (CRIS) Q1 2021 Earnings Call Transcript
Revenue
$2.19M
▼ 19.2% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Curis Inc (CRIS) Q4 2020 Earnings Call Transcript
Revenue
$3.02M
▼ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Curis Inc (CRIS) Q3 2020 Earnings Call Transcript
Revenue
$2.74M
▼ 4% YoY Diluted EPS
$-2.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Curis Inc (CRIS) Q2 2020 Earnings Call Transcript
Revenue
$2.36M
▲ 12.7% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Curis Inc (CRIS) Q1 2020 Earnings Call Transcript
Revenue
$2.71M
▲ 53.3% YoY Diluted EPS
$-5.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
Curis Inc (CRIS) Q4 2019 Earnings Call
Revenue
$3.29M
▲ 19.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 webcasts